Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMBER-4: imlunestrant versus standard adjuvant endocrine therapy in high-risk ER-positive, HER2-negative early breast cancer
NL-OMON61103Phase 3Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of imlunestrant in breast cancer (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Invasive disease-free survival. Started May 2023; status: active, not recruiting.
02
Drugs
imlunestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON61103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61103.